This proposal worries many in the industry because some genes that are potentially dangerous may not appear in the database and because developments in gene splicing may create new dangers that are not reflected in the computer database. Of greatest concern for the companies is cost; having human verification as well as automated verification would require more money. If several companies adopt only the automated verification, the industry as a whole would tend toward this "lowest common denominator" of regulation in order for their prices to stay competitive.
The issue will be resolved in November when the IASB will meet to discuss adopting an industry wide code of conduct. It is hoped that the US government, which has been studying possible codes of conduct, will offer an opinion that will help guide the proceedings. Human verification would likely be more effective than a computer database alone, but any industry wide code of conduct seems reassuring that dangerous genes cannot be purchased as easily by just anyone.